Brigatinib
Aliases
Alunbrig, AP26113
5 clinical trials
7 abstracts
18 indications
Indication
Lung CancerIndication
ALK Gene RearrangementIndication
Non-Small Cell Lung CarcinomaIndication
Recurrent Lung Non-Small Cell CarcinomaIndication
Stage IV Lung CancerIndication
Lung Cancer Stage IVA AJCC v8Indication
Breast CancerIndication
Gastrointestinal CancerIndication
CancerIndication
Neurofibromatosis Type 2Indication
Acoustic NeuromaIndication
SchwannomaIndication
MeningiomaIndication
EpendymomaIndication
lung cancerIndication
NSCLCIndication
Non-Small Cell Lung Cancer Stage IIIBIndication
Non-Small Cell Lung Cancer Stage IVClinical trial
BRIGHTSTAR: A Pilot Trial of Local Consolidative Therapy (LCT) With Brigatinib in Tyrosine Kinase Inhibitor-Naive ALK-Rearranged Advanced NSCLCStatus: Active (not recruiting), Estimated PCD: 2026-01-28
Abstract
Brigatinib monotherapy in children with R/R ALK+ ALCL, IMT, or other solid tumors: Results from the BrigaPED (ITCC-098) phase 1 study.Org: Princess Máxima Center for Pediatric Oncology, Erasmus MC-Sophia Children’s Hospital, University Medical Center Hamburg-Eppendorf, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Children University Hospital,
Abstract
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).Org: Yale New Haven Hospital, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Princess Margaret Cancer Centre, University Health Network, Massachusetts General Hospital,
Abstract
Timing of EGFR or ALK inhibitor initiation and survival among patients with advanced NSCLC.Org: Department of Thoracic Oncology, Kanagawa Cancer Center, H. Lee Moffitt Cancer Center and Research Institute,
Clinical trial
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)Status: Recruiting, Estimated PCD: 2029-12-01
Clinical trial
Clinical Utility of Liquid Biopsy as a Tool to Assess the Evolution of Brigatinib Treated Patients With Non-small Cell Lung Cancer With EML4-ALK Translocation: an Exploratory StudyStatus: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
Brigatinib in ALK-positive NSCLC Identified Via Blood-based AssaysStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Abstract
Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant.Org: Hospital Universitario Puerta de Hierro-Majadahonda, Hospital Universitario A Coruña, Son Espases University Hospital, Hospital Regional Carlos Haya, Catalan Institute of Oncology-Hospitalet,
Abstract
Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC in the ALTA-1L and J-ALTA studies.Org: University of Colorado Cancer Center, Sendai Kousei Hospital, Fujita Health University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Yonsei Cancer Center, Yonsei University Health System,
Abstract
Longitudinal tracking of ALK-positive lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA in the BRIGHTSTAR clinical trial.Org: University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Lucence Health, Inc., Lucence Health Inc, Lucence Diagnostics Pte. Ltd.,
Abstract
A real-world study of ALK fusion detection, treatment patterns, and survival outcomes of patients with advanced non–small-cell lung cancer (aNSCLC) in Brazil.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Oncoclinícas, Oncoclínicas Bahia, Hospital Santa Izabel,